Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

RecruitingRare disease

Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

Registered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a treatment for patients with a type of cancer known as neuroendocrine tumors. These tumors are graded as I and II, which refers to their growth rate and how they look under a microscope. The treatment being studied involves a combination of medications, including Octreotide, Lanreotide, and Lutetium (177Lu) Oxodotreotide. Octreotide and Lanreotide are known as somatostatin analogs, which are substances that mimic a natural hormone in the body to help control tumor growth. Lutetium (177Lu) Oxodotreotide is a type of targeted therapy that delivers radiation directly to the tumor cells.

The purpose of this study is to understand how the continued use of long-acting somatostatin analogs affects the amount of radiation absorbed by the tumor during a treatment called Peptide Receptor Radionuclide Therapy (PRRT). PRRT is a type of therapy that uses a small amount of radioactive material to target and kill cancer cells. The study will involve administering these medications to patients and monitoring the effects on their tumors over a period of time. The medications will be given through injections, with Octreotide administered intramuscularly, Lanreotide subcutaneously, and Lutetium (177Lu) Oxodotreotide intravenously.

Throughout the study, patients will undergo imaging tests to measure the radiation absorbed by the tumors and other tissues in the body. These tests will help researchers understand how the treatment affects both the cancer and the surrounding healthy tissues. The study aims to provide valuable insights into the effectiveness and safety of using these medications together in treating neuroendocrine tumors.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, you will undergo an initial assessment to confirm eligibility. This includes verifying your age, medical history, and diagnosis of a neuroendocrine tumor. You must be 18 years or older and able to provide informed consent.

    A physical examination and imaging tests will be conducted to ensure you meet the criteria, such as having at least one soft tissue lesion greater than 2 cm.

  2. Step 2

    Treatment planning

    A treatment plan will be developed, which includes the administration of lutetium (177lu) oxodotreotide through an intravenous route. The aimed administered activity is 7400 MBq.

    You will also continue using long-acting somatostatin analogues, such as octreotide or lanreotide, which are administered via intramuscular injection or subcutaneous routes.

  3. Step 3

    Treatment administration

    The treatment involves receiving the lutetium (177lu) oxodotreotide intravenously. This process will be repeated as per the treatment schedule provided by the medical team.

    You will continue receiving the long-acting somatostatin analogues at the prescribed dosage and frequency throughout the trial.

  4. Step 4

    Monitoring and imaging

    Regular monitoring will be conducted to assess the absorbed dose in tumor lesions and normal tissues using SPECT/CT imaging. This helps in evaluating the treatment's effectiveness and safety.

    Blood samples will be taken to determine the bone marrow dose and to assist in pharmacokinetic modeling.

  5. Step 5

    Follow-up and evaluation

    After completing the treatment cycles, follow-up visits will be scheduled to monitor your health and the treatment's impact on the tumor.

    The study aims to continue until November 2026, with regular assessments to ensure your well-being and gather necessary data.

Who can join the trial?

7 criteria

  • Must be 18 years or older.
  • Must be able to provide spoken and written consent to participate in the trial.
  • Must have a neuroendocrine tumor confirmed by a tissue examination.
  • Must meet the clinical criteria for PRRT (a specific type of treatment for certain tumors).
  • Must have at least one soft tissue lesion that is larger than 2 cm (about 0.8 inches).
  • The planned treatment involves an administered activity of 7400 MBq (a measure of the amount of radioactive substance used in treatment).
  • Must have an ECOG score of 0 to 2, which means the patient is fully active or has some symptoms but can still take care of themselves.

Who cannot join the trial?

3 criteria

  • Patients who are under 18 years old cannot participate.
  • Patients who do not have a neuroendocrine tumor of grade I or II cannot participate. A neuroendocrine tumor is a type of tumor that can occur in hormone-producing cells.
  • Patients who do not have a clinical indication for PRRT cannot participate. PRRT stands for Peptide Receptor Radionuclide Therapy, a type of treatment for certain tumors.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Peptide Receptor Radionuclide Therapy (PRRT)

    is a type of treatment that uses a small amount of radioactive material to target and kill cancer cells. It works by attaching the radioactive material to a molecule that can find and bind to specific receptors on the surface of cancer cells. This allows the radiation to be delivered directly to the tumor, minimizing damage to healthy tissues. In this trial, PRRT is being used to treat tumors that have specific receptors for somatostatin, a hormone that regulates various bodily functions.

  • Long-acting Somatostatin Analogues (LA-SSA)

    are medications that mimic the action of somatostatin, a natural hormone in the body. These analogues are designed to last longer in the body, providing a sustained effect. They work by binding to the same receptors as somatostatin, helping to control the growth of certain types of tumors. In this trial, LA-SSA is used to see how it affects the amount of radiation absorbed by the tumor during PRRT.

What is already known about the treatment

Long-acting Somatostatin Analogues – This medication is administered through an injection and is used in the treatment of neuroendocrine tumors, specifically for patients over 18 years old with grade I and II tumors. It is currently being studied in clinical trials to understand its effect on the absorbed dose in tumor lesions during Peptide Receptor Radionuclide Therapy (PRRT). The main therapeutic use of this medication is to help manage symptoms and slow the growth of neuroendocrine tumors. At the molecular level, it works by mimicking the action of somatostatin, a hormone that inhibits the release of several other hormones, thereby reducing tumor growth and hormone-related symptoms. It is classified pharmacologically as a somatostatin analogue.

Investigated diseases

Neuroendocrine Tumor – Neuroendocrine tumors are a type of growth that arises from cells of the neuroendocrine system, which is responsible for producing hormones. These tumors can occur in various parts of the body, including the gastrointestinal tract, pancreas, and lungs. They are classified into different grades based on how quickly they grow and spread, with Grade I and II being slower-growing forms. As the tumor progresses, it may cause symptoms related to hormone overproduction or due to its size and location, such as abdominal pain or changes in bowel habits. Over time, these tumors can metastasize, meaning they spread to other parts of the body. The progression of symptoms and tumor growth can vary significantly among individuals.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-505884-35-00Estimated enrolment34 patientsSponsorHet Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.